Business
BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced two poster presentations featuring BBO-10203, a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction, at the San Antonio Breast Cancer Symposium (SABCS) being held December 9-12, 2025, in San Antonio, Texas. The abstracts released today can be fou
About this update from Bridgebio Oncology Therapeutics, Inc.
[{"type":"image","alt":"TheRas, Inc. (d/b/a BBOT)","displaySize":"","headline":null,"caption":"TheRas, Inc. (d/b/a BBOT)","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":143,"url":"https://media.zenfs.com/en/globenewswire.com/9479f198b092ba1412cb0ee76f46ca4a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fHlO5lqk7Y3zBP.mSEEEmg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIwMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9479f198b092ba1412cb0ee76f46ca4a","width":300,"height":143}},"lazy":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced two poster presentations featuring BBO-10203, a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction, at the San Antonio Breast Cancer Symposium (SABCS) being held December 9-12, 2025, in San Antonio, Texas. The abstracts released today can be found on the SABCS website here.","length":534,"tagName":"p"},{"type":"text","content":"Late Breaking Pre-clinical Poster Details: ","length":42,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Title: BBO-10203, a first-in-class breaker of the RAS:PI3Kα interaction, inhibits tumor growth alone and in combination with fulvestrant or ribociclib in breast cancer models without inducing hyperglycemia","length":205,"tagName":"p"}]},{"val":[{"type":"text","content":"Presentation Number: PS2-12-06","length":30,"tagName":"p"}]},{"val":[{"type":"text","content":"Abstract Number: 3568","length":21,"tagName":"p"}]},{"val":[{"type":"text","content":"Session Date/Time: Wednesday, December 10, from 5:00 p.m. - 6:30 p.m. CT","length":72,"tagName":"p"}]},{"val":[{"type":"text","content":"Presenter: Kerstin Sinkevicius, PhD, Vice President, Pharmacology, BBOT","length":71,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":399,"olType":false},{"type":"text","content":"Trials in Progress Poster Details:","length":34,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Title: BREAKER-101: a phase 1a/1b open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of BBO-10203 in patients with advanced solid tumors","length":170,"tagName":"p"}]},{"v...